Today’s Price Action: Time to Buy Agios Pharmaceuticals Inc After Today’s Significant Decline?

Today's Price Action: Time to Buy Agios Pharmaceuticals Inc After Today's Significant Decline?

The stock of Agios Pharmaceuticals Inc (NASDAQ:AGIO) is a huge mover today! About 416,202 shares traded hands. Agios Pharmaceuticals Inc (NASDAQ:AGIO) has risen 34.66% since March 9, 2016 and is uptrending. It has outperformed by 27.25% the S&P500.
The move comes after 8 months negative chart setup for the $2.02 billion company. It was reported on Oct, 12 by Barchart.com. We have $46.97 PT which if reached, will make NASDAQ:AGIO worth $141.40M less.

Analysts await Agios Pharmaceuticals Inc (NASDAQ:AGIO) to report earnings on November, 3. They expect $-1.44 earnings per share, down 34.58% or $0.37 from last year’s $-1.07 per share. After $-1.47 actual earnings per share reported by Agios Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -2.04% EPS growth.

Agios Pharmaceuticals Inc (NASDAQ:AGIO) Ratings Coverage

Out of 11 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 6 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 55% are positive. Agios Pharmaceuticals has been the topic of 19 analyst reports since July 23, 2015 according to StockzIntelligence Inc. The firm has “Neutral” rating by BTIG Research given on Friday, August 19. Roth Capital maintained Agios Pharmaceuticals Inc (NASDAQ:AGIO) on Wednesday, August 5 with “Hold” rating. The firm earned “Buy” rating on Wednesday, May 18 by Suntrust Robinson. SunTrust initiated Agios Pharmaceuticals Inc (NASDAQ:AGIO) on Wednesday, March 30 with “Buy” rating. JP Morgan upgraded Agios Pharmaceuticals Inc (NASDAQ:AGIO) on Monday, June 13 to “Overweight” rating. The stock of Agios Pharmaceuticals Inc (NASDAQ:AGIO) has “Buy” rating given on Monday, June 13 by Canaccord Genuity. On Monday, December 7 the stock rating was downgraded by Leerink Swann to “Market Perform”. Canaccord Genuity maintained it with “Hold” rating and $93 target price in Friday, August 7 report. The company was initiated on Wednesday, March 2 by Janney Capital. Roth Capital maintained Agios Pharmaceuticals Inc (NASDAQ:AGIO) on Monday, November 9 with “Neutral” rating.

According to Zacks Investment Research, “Agios Pharmaceuticals, Inc. is a biopharmaceutical company. It discovers and develops therapeutics in the field of cancer metabolism and inborn errors of metabolism. The Company’s products include AG-221, AG-120, enzyme glutaminase and AG-348. Agios Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.”

Insitutional Activity: The institutional sentiment increased to 1.39 in Q2 2016. Its up 0.03, from 1.36 in 2016Q1. The ratio increased, as 22 funds sold all Agios Pharmaceuticals Inc shares owned while 37 reduced positions. 18 funds bought stakes while 64 increased positions. They now own 35.06 million shares or 11.59% more from 31.42 million shares in 2016Q1.
Art Limited Liability accumulated 0.02% or 10,202 shares. Natl Bank Of America De last reported 0% of its portfolio in the stock. Ray Gerald L Ltd has 0.23% invested in the company for 34,465 shares. Alliancebernstein Ltd Partnership has invested 0% of its portfolio in Agios Pharmaceuticals Inc (NASDAQ:AGIO). Profund Advsr Lc has 0.03% invested in the company for 14,381 shares. Creative Planning reported 8,179 shares or 0% of all its holdings. Legal And General Group Incorporated Public Ltd Limited Liability Company holds 1,680 shares or 0% of its portfolio. Susquehanna International Grp Llp holds 45,839 shares or 0% of its portfolio. Blackrock Advsr Limited Liability Co last reported 253,023 shares in the company. Artal Sa accumulated 0.32% or 375,000 shares. Schwab Charles Mngmt Incorporated holds 0% of its portfolio in Agios Pharmaceuticals Inc (NASDAQ:AGIO) for 53,619 shares. Utah Retirement owns 5,100 shares or 0.01% of their US portfolio. Wells Fargo And Mn accumulated 13,996 shares or 0% of the stock. California State Teachers Retirement Systems accumulated 59,941 shares or 0.01% of the stock. Ladenburg Thalmann Svcs has 0% invested in the company for 127 shares.

Insider Transactions: Since April 25, 2016, the stock had 0 insider purchases, and 8 selling transactions for $2.91 million net activity. $129,432 worth of Agios Pharmaceuticals Inc (NASDAQ:AGIO) shares were sold by Cantley Lewis Clayton Jr.. $275,000 worth of Agios Pharmaceuticals Inc (NASDAQ:AGIO) was sold by Biller Scott.

More notable recent Agios Pharmaceuticals Inc (NASDAQ:AGIO) news were published by: Fool.com which released: “Why Agios Pharmaceuticals Inc Stock Skyrocketed Today” on September 07, 2016, also Fool.com with their article: “3 Big Reasons Agios Pharmaceuticals, Inc. Has Plunged 38% in 2016” published on July 03, 2016, Fool.com published: “Why Agios Pharmaceuticals Inc. Presented Lower Today” on June 09, 2016. More interesting news about Agios Pharmaceuticals Inc (NASDAQ:AGIO) were released by: Fool.com and their article: “A Short Squeeze and the Rumor Mill Stir Up Agios Pharmaceuticals, Inc. in April” published on May 06, 2016 as well as Streetinsider.com‘s news article titled: “Agios Pharma (AGIO), Celgene (CELG) Enter IDH Mutations Identification …” with publication date: October 12, 2016.

AGIO Company Profile

Agios Pharmaceuticals, Inc., incorporated on August 7, 2007, is a biopharmaceutical company. The Firm is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs), which are a subset of orphan genetic metabolic diseases. The Company’s cancer product candidates are AG-221 and AG-120, which targets mutated isocitrate dehydrogenase 2 and 1, or IDH2 and IDH1, respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2. These mutations are found in a range of hematological malignancies and solid tumors. The lead product candidate in its RGD programs, AG-348, which targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment